Skip to content

ABBOTT

Active
Public limited companyfounded 1948active for 78 yearsAvenue Einstein 14, 1300 Wavre, BelgiumKBO/BCE: BE 0403.044.007
Summary

ABBOTT has been active since 1948 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €2.10bn and a net result of €369.8m. Equity remains stable across the filed financial years (±0.3% per year). Its solvency ranks better than 93% of 6,152 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).

Overview

Activity
Wholesale of pharmaceutical and medical goods
NACE 46460
Largest company by total assets in Walloon Brabant, Wholesale and retail trade sector1 site
Size
€105.6mturnover 2025
Staff
71.2 FTE
Equity
€2.10bn
Profit
€369.8m
Financial health
91 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
0.2%
Structure
Parent
ABBOTT LABORATORIES
Holdings
9
Auditor: Ernst & Young Réviseurs d'Entreprises SRL2025 accounts 28 days early11 of 67 deeds summarised
Why 91raises riskLiquidity: current ratio 0.19, cash €1.1m, halved1 of the last 3 latelowers riskFounded in 1948Size: turnover €105.6m, 71.2 FTE, total assets €2.34bnShow the evidence

Checked score

Score 2025
91 / 100
Excellent
Probability in this band: under 0.55%
Financially better than 61% of its sector peers (NACE 46, medium-sized)
Financial strength · tick = 2024
Strong
Solvency 100=
equity 90.0% of total assets
Liquidity 50=
short-term debt 9.9% · cash 0.0%
Profitability 49+20
return on assets 15.8%
Bankruptcy probability, 12 months
0.2% Very low
0%0.5%1.5%4%10%≥ 25%

About 2 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.2% (746 companies, NACE 46, medium-sized)
Last 24 months 11-2024: 0.2% 12-2024: 0.2%● unchanged vs 11-2024 01-2025: 0.2%● unchanged vs 12-2024 02-2025: 0.2%● unchanged vs 01-2025 03-2025: 0.2%● unchanged vs 02-2025 04-2025: 0.2%● unchanged vs 03-2025 05-2025: 0.2%● unchanged vs 04-2025 06-2025: 0.2%● unchanged vs 05-2025 07-2025: 0.3%▲ +0.1 percentage points vs 06-2025 08-2025: 0.4%▲ +0.1 percentage points vs 07-2025highest value 09-2025: 0.4%● unchanged vs 08-2025highest value 10-2025: 0.4%● unchanged vs 09-2025highest value 11-2025: 0.4%● unchanged vs 10-2025highest value 12-2025: 0.4%● unchanged vs 11-2025highest value 01-2026: 0.4%● unchanged vs 12-2025highest value 02-2026: 0.4%● unchanged vs 01-2026 03-2026: 0.4%● unchanged vs 02-2026 04-2026: 0.4%● unchanged vs 03-2026 05-2026: 0.4%● unchanged vs 04-2026 06-2026: 0.4%● unchanged vs 05-2026 07-2026: 0.4%● unchanged vs 06-2026 08-2026: 0.2%▼ -0.2 percentage points vs 07-2026lowest value 09-2026: 0.2%● unchanged vs 08-2026lowest value 10-2026: 0.2%● unchanged vs 09-2026lowest value
Credit of up to €10,550,000 on 30-day terms is acceptable
Liquidity insufficient (current ratio 0.19, compared with 0.18 in 2024, below 1; short-term debt: 9.9% and cash: 0% of total assets), and 10% of the assets are financed with debt and provisions.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 46, medium-sized): better than 93% on solvency, 71% on liquidity, 31% on profitability and 50% on growth.

The bankruptcy probability was computed on 28-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Five signals.
lowers riskraises riskneutral
raises risk · Liquidity: current ratio 0.19, cash €1.1m, halved
NBB · annual accounts
lowers risk · Founded in 1948
Companies that have existed this long fail less often; how much that weighs depends on the rest of its profile.
KBO
lowers risk · Size: turnover €105.6m, 71.2 FTE, total assets €2.34bn
Companies of this size fail less often; how much that weighs depends on the rest of its profile.
NBB · annual accounts
raises risk · 1 of the last 3 late
NBB · filings
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 03-07-2026, 28 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
28 days early
2024
134 days late
2023
21 days early
2022
26 days early
2021
23 days late
2020
4 days early
2019
54 days late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 19 days after the deadline; the sector median (NACE 46) for financial year 2024 is 3 days before the deadline, and 39% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 11 July (4 of the last 5 filed years within 43 days of that day).
Companies Code · seven months
Where today falls in the filing period
29-10-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
Searched since 2021.
KBO publications · our coverage
  1. Annual accounts filedfinancial year 2025 · full…
  2. Resignations & appointmentsPower of attorney
  3. Resignation: Hendrikus Lueb (director)Appointment: Maya Abdel Ahad Wakim…

Financials · financial year 2025, full format

Turnover
€105.6m▲ 7.4%
2024 · €98.3m
EBIT margin
4.1%▲ 1.8pp
2024 · 2.3%
Net result
€369.8m
2024 · -€5.4m
Working capital
-€187.9m▼ 0.3%
2024 · -€187.4m
Trend over the years

2021 to 2025, 5 financial years 2019 to 2025, 6 financial years

After the dip in 2022 the operating result has climbed three years in a row; 2025 is 94% above 2024 and is the highest result in the available series.

What the company sold each financial year and what was left of it. A loss stands below the zero line.

Turnover€105.6m 2025 Operating result€4.3m 2025 Net result€369.8m 2025

Use the arrow keys on the chart for the figures per year.

Sector: the middle half of NACE 46, Wholesale trade: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Solvency, Current ratio, Return on assets (ROA), Staff (FTE).

Every figure with its change against the financial year before
favourable unfavourable
Line201920212022202320242025
Turnover€78.8m-€94.1m-€91.4m▼ 2.9%€93.6m▲ 2.5%€98.3m▲ 5.0%€105.6m▲ 7.4%
Operating result€1.7m-€1.7m-€0.3m▼ 80.1%€2.1m▲ 533%€2.2m▲ 5.3%€4.3m▲ 94.0%
Net result€496.5m-€66.2mabove the sector's middle half-€217.8mabove the sector's middle half▲ 229%-€4.3mbelow the sector's middle half-€5.4mbelow the sector's middle half▼ 26.5%€369.8mabove the sector's middle half
EBIT margin2.2%-1.8%-0.4%▼ 1.4pp2.3%▲ 1.9pp2.3%=4.1%▲ 1.8pp
Equity€2,140.3m-€2,142.5mabove the sector's middle half-€2,114.2mabove the sector's middle half▼ 1.3%€2,109.9mabove the sector's middle half▼ 0.2%€2,108.1mabove the sector's middle half▼ 0.1%€2,104.8mabove the sector's middle half▼ 0.2%
Total assets€3,379.0m-€2,326.6mabove the sector's middle half-€2,328.8mabove the sector's middle half▲ 0.1%€2,335.8mabove the sector's middle half▲ 0.3%€2,339.1mabove the sector's middle half▲ 0.1%€2,338.1mabove the sector's middle half=
Debt€1,238.2m-€183.7m-€214.3m▲ 16.6%€225.2m▲ 5.1%€230.1m▲ 2.2%€232.1m▲ 0.9%
Working capital-€150.2m--€152.3mbelow the sector's middle half--€181.8mbelow the sector's middle half▼ 19.4%-€185.6mbelow the sector's middle half▼ 2.1%-€187.4mbelow the sector's middle half▼ 0.9%-€187.9mbelow the sector's middle half▼ 0.3%
Solvency63.3%-92.1%above the sector's middle half-90.8%above the sector's middle half▼ 1.3pp90.3%above the sector's middle half▼ 0.5pp90.1%above the sector's middle half▼ 0.2pp90.0%above the sector's middle half▼ 0.1pp
Current ratio0.88-0.17below the sector's middle half-0.15below the sector's middle half▼ 0.020.17below the sector's middle half▲ 0.030.18below the sector's middle half▲ 0.010.19below the sector's middle half=
Return on assets (ROA)14.7%-2.8%within the sector's middle half-9.4%within the sector's middle half▲ 6.5pp-0.2%below the sector's middle half▼ 9.5pp-0.2%below the sector's middle half=15.8%above the sector's middle half▲ 16.0pp
Staff (FTE)85.7-82.5above the sector's middle half-87.3above the sector's middle half▲ 5.8%775above the sector's middle half▲ 788%75.8above the sector's middle half▼ 90.2%71.2above the sector's middle half▼ 6.1%
above within below the middle half of NACE 46, Wholesale trade: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €2.34bn
Fixed assets €2.30bn ▼ 0.1%
Current assets €43.0m ▲ 3.1%
Equity and liabilities €2.34bn
Equity €2.10bn ▼ 0.2%
Provisions €1.2m ▲ 21.9%
Debt €232.1m ▲ 0.9%
Debt's share of the balance-sheet total rises from 9.8% to 9.9%. Equity is lower and debt is higher.
Key figures and ratios
2025 value · change against 2024
EBITDA
€6.8m▲
2024 · €4.9m
Cash flow
€372.3m▲
2024 · -€2.7m
Quick ratio
0.18▲
2024 · 0.18
Debt to equity
0.11▲
2024 · 0.11
ROE
17.6%▲
2024 · -0.3%
Interest coverage
1.44▲
2024 · 0.65
Debt ≤ 1 year
€230.9m▲
2024 · €229.1m
Income taxes
-€840,128▼
2024 · €137,733
Staff costs
€13.7m▲
2024 · €13.0m
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Annual accounts
Filed annual accounts As filed with the NBB · 2025 against 2024 · 76 lines
Balance sheet Code20242025
Assets
Total assets20/58€2,339.1m€2,338.1m=
Fixed assets21/28€2,297.4m€2,295.1m▼
Intangible fixed assets21€0.2m€0.2m=
Tangible fixed assets22/27€16.0m€13.7m▼
Furniture and vehicles24€0.3m€0.3m▲
Other tangible fixed assets26€15.7m€13.4m▼
Assets under construction and advance payments27-€0.003m
Financial fixed assets28€2,281.2m€2,281.2m=
Affiliated companies280/1€2,280.1m€2,280.1m=
Participating interests280€2,280.1m€2,280.1m=
Other financial fixed assets284/8€1.1m€1.1m▼
Amounts receivable and cash guarantees285/8€1.1m€1.1m▼
Current assets29/58€41.7m€43.0m▲
Stocks and contracts in progress3€1.1m€0.7m▼
Stocks30/36€1.1m€0.7m▼
Goods purchased for resale34€1.1m€0.7m▼
Amounts receivable within one year40/41€37.8m€41.1m▲
Trade receivables40€37.6m€41.0m▲
Other amounts receivable41€0.2m€0.08m▼
Cash at bank and in hand54/58€2.6m€1.1m▼
Deferred charges and accrued income490/1€0.2m€0.2m▲
Equity and liabilities
Total equity and liabilities10/49€2,339.1m€2,338.1m=
Equity10/15€2,108.1m€2,104.8m▼
Contributions10/11€3,014.6m€2,645.2m▼
Capital10€3,014.6m€2,645.2m▼
Issued capital100€3,014.6m€2,645.2m▼
Reserves13€47.1m€47.1m=
Non-distributable reserves130/1€47.1m€47.1m=
Legal reserve130€47.1m€47.1m=
Other1319€0.001m€0.001m=
Profit (loss) carried forward14-€953.7m-€587.5m▲
Provisions and deferred taxes16€1.0m€1.2m▲
Provisions for liabilities and charges160/5€1.0m€1.2m▲
Other liabilities and charges164/5€1.0m€1.2m▲
Amounts payable17/49€230.1m€232.1m▲
Amounts payable within one year42/48€229.1m€230.9m▲
Trade debts44€15.5m€13.1m▼
Suppliers440/4€15.5m€13.1m▼
Taxes, remuneration and social security45€3.9m€5.2m▲
Taxes450/3€0.3m€1.2m▲
Remuneration and social security454/9€3.6m€4.0m▲
Other amounts payable47/48€209.7m€212.6m▲
Accrued charges and deferred income492/3€1.0m€1.2m▲
Income statement Code20242025
Operating income70/76A€100.0m€107.3m▲
Turnover70€98.3m€105.6m▲
Other operating income74€1.7m€1.7m▼
Operating charges60/66A€97.8m€103.0m▲
Goods for resale, raw materials and consumables60€71.8m€76.5m▲
Purchases600/8€70.9m€75.4m▲
Change in stocks: decrease (increase)609€0.9m€1.1m▲
Services and other goods61€9.9m€9.9m▼
Remuneration, social security and pensions62€13.0m€13.7m▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€2.7m€2.5m▼
Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4€0.2m-€0.2m▼
Provisions for liabilities and charges: additions (uses and reversals)635/8-€0.01m€0.2m▲
Other operating charges640/8€0.2m€0.3m▲
Non-recurring operating charges66A€0.003m€0.06m▲
Operating profit (loss)9901€2.2m€4.3m▲
Financial income75/76B€0.1m€369.5m▲
Recurring financial income75€0.1m€369.5m▲
Income from financial fixed assets750-€369.5m
Other financial income752/9€0.1m-
Non-recurring financial income76B-€0.006m
Financial charges65/66B€7.6m€4.8m▼
Recurring financial charges65€7.6m€4.8m▼
Debt charges650€7.6m€4.7m▼
Other financial charges652/9€0.03m€0.06m▲
Profit (loss) for the period before taxes9903-€5.3m€369.0m▲
Income taxes67/77€0.1m-€0.8m▼
Taxes670/3€0.1m-
Tax adjustments and reversals of tax provisions77-€0.8m
Profit (loss) for the period9904-€5.4m€369.8m▲
Profit (loss) for the period to be appropriated9905-€5.4m€369.8m▲
Appropriation of the result
Profit (loss) to be appropriated9906-€953.7m-€587.5m▲
Profit (loss) brought forward from the previous period14P-€948.3m-€957.3m▼
Social balance sheet
Average headcount (FTE)908775.871.2▼

The notes to these accounts (51 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Line201920212022202320242025Change
Operating income70/76A€81.2m€95.8m€93.1m€95.6m€100.0m€107.3m▲ 7.3%
Turnover70€78.8m€94.1m€91.4m€93.6m€98.3m€105.6m▲ 7.4%
Other operating income74€2.3m€1.7m€1.7m€2.0m€1.7m€1.7m▼ 0.3%
Operating charges60/66A€79.4m€94.1m€92.8m€93.5m€97.8m€103.0m▲ 5.3%
Goods for resale, raw materials and consumables60€57.2m€72.1m€69.0m€65.6m€71.8m€76.5m▲ 6.6%
Purchases600/8---€64.7m€70.9m€75.4m▲ 6.4%
Change in stocks: decrease (increase)609-€0.1m€0.7m€0.6m€1.0m€0.9m€1.1m▲ 24.2%
Services and other goods61€6.6m€7.0m€7.1m€8.3m€9.9m€9.9m▼ 0.1%
Remuneration, social security and pensions62€13.1m€11.7m€13.5m€13.5m€13.0m€13.7m▲ 5.8%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€1.9m€2.1m€2.1m€2.5m€2.7m€2.5m▼ 7.6%
Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4€0.07m€0.4m€0.09m€0.4m€0.2m-€0.2m-
Provisions for liabilities and charges: additions (uses and reversals)635/8€0.04m€0.1m-€0.08m€2.2m-€0.01m€0.2m-
Other operating charges640/8€0.2m€0.8m€1.0m€0.9m€0.2m€0.3m▲ 36.0%
Non-recurring operating charges66A€0.2m€0.02m€0.02m€0.002m€0.003m€0.06m▲ 21×
Operating profit (loss)9901€1.7m€1.7m€0.3m€2.1m€2.2m€4.3m▲ 94.0%
Financial income75/76B---€0.05m€0.1m€369.5m▲ 2,798×
Recurring financial income75€500.4m€65.1m€219.8m€0.05m€0.1m€369.5m▲ 2,798×
Income from financial fixed assets750€500.0m€65.0m€219.8m--€369.5m-
Income from current assets751€0.4m------
Other financial income752/9€0.04m€0.07m-€0.05m€0.1m--
Non-recurring financial income76B€0.01m€0.04m---€0.006m-
Financial charges65/66B€5.2m€0.4m€1.7m€7.0m€7.6m€4.8m▼ 37.1%
Recurring financial charges65€1.1m€0.4m€1.7m€7.0m€7.6m€4.8m▼ 37.1%
Debt charges650€0.7m€0.09m€0.6m€6.8m€7.6m€4.7m▼ 37.7%
Other financial charges652/9€0.3m€0.3m€1.2m€0.1m€0.03m€0.06m▲ 102%
Non-recurring financial charges66B€4.2m------
Profit (loss) for the period before taxes9903€496.9m€66.4m€218.4m-€4.8m-€5.3m€369.0m-
Income taxes67/77€0.4m€0.2m€0.6m-€0.5m€0.1m-€0.8m-
Taxes670/3€0.4m€0.2m€0.6m-€0.1m--
Tax adjustments and reversals of tax provisions77---€0.5m-€0.8m-
Profit (loss) for the period9904€496.5m€66.2m€217.8m-€4.3m-€5.4m€369.8m-
Profit (loss) for the period to be appropriated9905€496.5m€66.2m€217.8m-€4.3m-€5.4m€369.8m-
Line201920212022202320242025Change
Assets
Total assets20/58€3,379.0m€2,326.6m€2,328.8m€2,335.8m€2,339.1m€2,338.1m=
Fixed assets21/28€2,291.6m€2,295.9m€2,297.2m€2,296.8m€2,297.4m€2,295.1m▼ 0.1%
Intangible fixed assets21-€0.002m€0.002m€0.2m€0.2m€0.2m=
Tangible fixed assets22/27€12.4m€13.6m€14.9m€15.3m€16.0m€13.7m▼ 14.4%
Furniture and vehicles24€0.1m€0.1m€0.2m€0.3m€0.3m€0.3m▲ 12.3%
Other tangible fixed assets26€10.8m€13.5m€14.7m€15.0m€15.7m€13.4m▼ 14.8%
Assets under construction and advance payments27€1.4m----€0.003m-
Financial fixed assets28€2,279.3m€2,282.3m€2,282.3m€2,281.3m€2,281.2m€2,281.2m=
Affiliated companies280/1€2,278.6m€2,281.4m€2,281.4m€2,280.1m€2,280.1m€2,280.1m=
Participating interests280€2,278.6m€2,281.4m€2,281.4m€2,280.1m€2,280.1m€2,280.1m=
Other financial fixed assets284/8€0.7m€0.9m€1.0m€1.2m€1.1m€1.1m▼ 0.6%
Amounts receivable and cash guarantees285/8€0.7m€0.9m€1.0m€1.2m€1.1m€1.1m▼ 0.6%
Current assets29/58€1,087.3m€30.7m€31.6m€39.0m€41.7m€43.0m▲ 3.1%
Stocks and contracts in progress3€1.2m€2.4m€1.6m€2.7m€1.1m€0.7m▼ 43.0%
Stocks30/36€1.2m€2.4m€1.6m€2.7m€1.1m€0.7m▼ 43.0%
Goods purchased for resale34€1.2m€2.4m€1.6m€2.7m€1.1m€0.7m▼ 43.0%
Amounts receivable within one year40/41€1,083.5m€25.5m€27.7m€31.7m€37.8m€41.1m▲ 8.7%
Trade receivables40€21.1m€23.9m€27.5m€31.5m€37.6m€41.0m▲ 9.1%
Other amounts receivable41€1,062.3m€1.6m€0.3m€0.2m€0.2m€0.08m▼ 60.7%
Cash at bank and in hand54/58€2.4m€2.8m€2.2m€4.5m€2.6m€1.1m▼ 58.6%
Deferred charges and accrued income490/1€0.2m--€0.1m€0.2m€0.2m▲ 11.6%
Equity and liabilities
Total equity and liabilities10/49€3,379.0m€2,326.6m€2,328.8m€2,335.8m€2,339.1m€2,338.1m=
Equity10/15€2,140.3m€2,142.5m€2,114.2m€2,109.9m€2,108.1m€2,104.8m▼ 0.2%
Contributions10/11€3,325.7m€3,260.7m€3,014.6m€3,014.6m€3,014.6m€2,645.2m▼ 12.3%
Capital10€3,325.7m€3,260.7m€3,014.6m€3,014.6m€3,014.6m€2,645.2m▼ 12.3%
Issued capital100€3,325.7m€3,260.7m€3,014.6m€3,014.6m€3,014.6m€2,645.2m▼ 12.3%
Reserves13€32.9m€36.2m€47.1m€47.1m€47.1m€47.1m=
Non-distributable reserves130/1-€36.2m€47.1m€47.1m€47.1m€47.1m=
Legal reserve130€32.9m€36.2m€47.1m€47.1m€47.1m€47.1m=
Reserves not available under the articles1311€0.001m------
Other1319-€0.001m€0.001m€0.001m€0.001m€0.001m=
Profit (loss) carried forward14-€1,218.3m-€1,154.5m-€947.6m-€951.9m-€953.7m-€587.5m▲ 38.4%
Provisions and deferred taxes16€0.4m€0.5m€0.4m€0.8m€1.0m€1.2m▲ 21.9%
Provisions for liabilities and charges160/5€0.4m€0.5m€0.4m€0.8m€1.0m€1.2m▲ 21.9%
Pensions and similar obligations160€0.08m------
Other liabilities and charges164/5€0.3m€0.5m€0.4m€0.8m€1.0m€1.2m▲ 21.9%
Amounts payable17/49€1,238.2m€183.7m€214.3m€225.2m€230.1m€232.1m▲ 0.9%
Amounts payable within one year42/48€1,237.5m€183.0m€213.3m€224.6m€229.1m€230.9m▲ 0.8%
Trade debts44€10.7m€9.0m€9.8m€15.1m€15.5m€13.1m▼ 15.6%
Suppliers440/4€10.7m€9.0m€9.8m€15.1m€15.5m€13.1m▼ 15.6%
Taxes, remuneration and social security45€5.3m€5.2m€6.6m€4.5m€3.9m€5.2m▲ 34.3%
Taxes450/3€1.6m€1.5m€2.8m€0.8m€0.3m€1.2m▲ 284%
Remuneration and social security454/9€3.7m€3.6m€3.8m€3.8m€3.6m€4.0m▲ 13.0%
Other amounts payable47/48€1,221.6m€168.8m€196.9m€205.0m€209.7m€212.6m▲ 1.4%
Accrued charges and deferred income492/3€0.7m€0.7m€0.9m€0.5m€1.0m€1.2m▲ 22.3%
Line201920212022202320242025Change
Profit (loss) for the period9904€496.5m€66.2m€217.8m-€4.3m-€5.4m€369.8m-
+ Depreciation and write-downs630€1.9m€2.1m€2.1m€2.5m€2.7m€2.5m▼ 7.6%
Operating cash flow (approximation)€498.4m€68.3m€219.9m-€1.8m-€2.7m€372.3m-
Investment in fixed assets (approximation)---€3.4m-€2.1m-€3.4m-€0.2m▲ 93.8%
Change in cash---€0.6m€2.2m-€1.9m-€1.5m▲ 19.6%

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Latest 10 of 49 filings with the National Bank
Financial year Type Filed Reference
31-12-2025 full format 03-07-2026 2026-00244956
31-12-2024 full format 12-12-2025 2025-00581178
31-12-2023 full format 10-07-2024 2024-00245182
31-12-2022 full format 05-07-2023 2023-00213064
31-12-2021 full format 23-08-2022 2022-20309821
31-12-2020 full format 27-07-2021 2021-42800478
31-12-2019 full format 23-09-2020 2020-55500164
31-12-2018 full format 30-12-2019 2019-77900550
31-12-2017 full format 27-09-2018 2018-66500521
31-12-2016 full format 29-06-2017 2017-25400270

Show all 49 filings

Similar companies · same sector, comparable size

Of the 1,866 active companies whose main activity is wholesale of pharmaceutical and medical goods (NACE 46460), figures are known for 1,128. 10 are within a factor 10 of this equity. These 5 are the closest to it. See the whole sector

Public contracts

7 awards · 2024 to 2026
CAPTEURS DE GLYCEMIE EN CONTINU
buyer: ASBL CHU HELORAMedical equipment and pharmaceuticalsawarded 14-05-2026€1.72bn3 tendersTED 713361-2026
Procédure ouverte pour la fourniture de capteurs et lecteurs de la glycémie pour le compte du SPF JUSTICE, Direction générale Etablissements Pénitentiaires – Service Soins de Santé Prisons - Pharmacie centrale: CSC n° 2026-2029 / Glycémie CGM - 1
buyer: FOD JustitieMedical equipment and pharmaceuticalsawarded 01-01-2026€664,1791 tenderTED 6155-2026
Automates de mesure du temps de coagulation (ACT)
buyer: ASBL CHU HELORALaboratory, optical and precision equipmentawarded 04-11-2025€346,4642 tendersTED 736205-2025
Raamovereenkomst voor het leveren van reagentia voor het uitvoeren van chemie- en immunochemie-analyses incl. toestellen in bruikleen: Het leveren van reagentia voor het uitvoeren van virale serologie-analyses incl. toestellen in bruikleen
buyer: Universitair Ziekenhuis GentMedical equipment and pharmaceuticalsawarded 18-02-2025€1.3m3 tendersTED 124214-2025
Raamcontract voor het leveren van reagentia voor ACT- en bloedgasmetingen, inclusief koppeling met het LIS via reeds aanwezige open middleware software, het leveren, plaatsen en in dienst stellen van toestellen in bruikleen: Reagentia voor ACT-metingen
buyer: Universitair Ziekenhuis GentMedical equipment and pharmaceuticalsawarded 28-02-2024€417,7602 tendersTED 125142-2025
Show 2 more contracts
Raamcontract voor het leveren van reagentia voor ACT- en bloedgasmetingen, inclusief koppeling met het LIS via reeds aanwezige open middleware software, het leveren, plaatsen en in dienst stellen van toestellen in bruikleen: Reagentia voor bloedgasmetingen
buyer: Universitair Ziekenhuis GentMedical equipment and pharmaceuticalsawarded 28-02-2024€47,0401 tenderTED 125142-2025
Lecteurs basal-bolus: CF11-23 - 1
buyer: Centre Hospitalier Bois de l'AbbayeLaboratory, optical and precision equipmentawarded 19-02-2024€20,6141 tenderTED 114906-2024

Source: TED (Tenders Electronic Daily), Publications Office of the European Union. Values as the buyer published them; for a framework agreement, a ceiling.

Directors

Directors
2 directors, 1 in day-to-day management, last change in 2026

Board 2

Bradley Jay Slater
Director · since 28-10-2022
Current
Maya Abdel Ahad Wakim
Director · since 01-01-2026
Current

Day-to-day management 1

Maya Abdel Ahad Wakim
Managing director · since 01-01-2026
Current

Statutory auditor 1

Ernst & Young Réviseurs d'Entreprises SRL
Statutory auditor · since 04-10-2023 · permanent representative: Piet Hemschoote
Current
Derived from published Gazette deeds. The KBO keeps the official list of office holders; we do not read it, so the two can differ. See the directors and other office holders in the KBO →
Not every act has been read: a resignation may still be missing
56 of this company's 67 Belgian Official Gazette deeds have not been read yet. Appointments and resignations recorded in them are not yet in the list of directors: someone who resigned there may still be listed as sitting. The acts are in the Timeline.

Mandate history

5 people since 2022, 3 in office
Show
  • Board
  • Day-to-day management
  • Statutory auditor
  • began earlier
Mandates per person, with start and end dates
Name Functions and periods
Bradley Jay Slater
  • Director, from 28-10-2022 to date
Maya Abdel Ahad Wakim
  • Director, from 01-01-2026 to date
  • Managing director, from 01-01-2026 to date
Ernst & Young Réviseurs d'Entreprises SRL
  • Statutory auditor, from 04-10-2023 to date
Hendrikus Lueb
  • Director, until 20-01-2026
  • Managing director, until 20-01-2026
Benjamin Edward Oosterbaan
  • Director, until 14-11-2022
See the board, name and registered office on a given date →

Owners and capital

Owners

3 owners

Chain of control

  1. ABBOTT LABORATORIESUS consolidated
  2. ABBOTT

Highest known parent: ABBOTT LABORATORIES (United States). The sources do not say who stands above it.

Owners 3

According to the 2025 annual accounts of ABBOTT and those of the other companies, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.

Capital and shareholders

Capital over the years
  1. 07-10-2025 Capital reduction of €369,454,545 · to €2,645,169,512.30 · repaid to the shareholders
  2. 31-10-2022 Capital reduction of €246,108,367 · to €3,014,624,057.30 · repaid to the shareholders

Group and network

Part of the group ABBOTT LABORATORIES 6 companies Group, risk and exposure

Holdings and subsidiaries

9 holdings

Holdings 9

Source for every holding own accounts 2025

  • ABBOTT ASIA INVESTMENTS LTDGBsubsidiary
    Equity GBP 1.69bnResult GBP 222.5m
    100%+ 0% via subsidiaries
  • ABBOTT LABORATORIOS LDAPTsubsidiary
    Equity €39.3mResult €2.6m
    100%+ 0% via subsidiaries
  • Equity €13.3mResult €3.7m
    100%+ 0% via subsidiaries
  • Abbott Medical HellasGRsubsidiary
    Equity €18.4mResult €669,538
    100%+ 0% via subsidiaries
  • Abbott Medical Italia SPAITsubsidiary
    Equity €109.5mResult €6.8m
    100%+ 0% via subsidiaries
  • Abbott Norge ASNOsubsidiary
    Equity NOK 132.7mResult NOK 20.9m
    100%+ 0% via subsidiaries
  • Equity €6.8mResult €317,389
    100%+ 0% via subsidiaries
  • ABBOTT srlITsubsidiary
    Equity €218.4mResult €16.8m
    100%+ 0% via subsidiaries
  • KNOLL UK INVESTMENTS UNLIMITEDGBsubsidiary
    Equity USD 221.1mResult USD 8.8m
    100%+ 0% via subsidiaries
Stated earlier (1)

An older source named these holdings; newer accounts no longer list them.

According to the 2025 annual accounts of ABBOTT and those of the other companies, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.

Connections & network

2 current directors
Depth

The board mandates are listed below; here you explore them as a network.

This company Company Director Shareholding +N: links not shown yet Click a node to look further, drag to arrange, zoom with the mouse wheel.

Board mandates elsewhere

1 board mandate
Board mandates of this companythis company sits on their board1

History

On 6 September 1948, ABBOTT was incorporated.1 Turnover went from €78.8m in 2019 to €105.6m in 2025 and headcount from 85.7 to 71.2 full-time equivalents.2

  1. 1KBO register
  2. 2National Bank, annual accounts 2019 and 2025

Acts, filings and financial milestones

Next filing, financial year 2026, expected by 31-07-2027
2026
03-07
NBB filing Annual accounts filed
financial year 2025 · full format
23-02
Gazette deed Resignations & appointments
Power of attorney3 facts ▸
  • Board meeting, 12-01-2026
  • Power of attorney, Freek Heuyerjans
  • Power of attorney, Frank Heyvaert
20-01
Gazette deed Resignation: Hendrikus Lueb (director)
Appointment: Maya Abdel Ahad Wakim (director) · Power of attorney7 facts ▸
  • General meeting, 17-12-2025
  • Director resignation, Hendrikus Lueb (director)
  • Director appointment, Maya Abdel Ahad Wakim (director)
  • Board meeting, 18-12-2025
  • Director resignation, Hendrikus Lueb (managing director)
  • Power of attorney, Hendrikus Lueb
  • Director appointment, Maya Abdel Ahad Wakim (managing director)
2025
31-12
Financial Back to profitnet €369.8m
Net result €369.8m after 2 loss-making years.
12-12
NBB filing Annual accounts filed
financial year 2024 · full format · 134 days late
07-10
Gazette deed Capital & shares · Amendment of the articles
Capital decrease · Capital4 facts ▸
  • General meeting, 03-10-2025
  • Capital decrease, €369,454,545
  • Capital, €2,645,169,512.30
  • Amendment of the articles, 5
2024
31-12
Financial Weakest financial yearnet -€5.4m
Net result drops to -€5.4m, the lowest in the series; recovery starts the following year.
30-10
Gazette deed Resignations & appointments
Power of attorney4 facts ▸
  • Board meeting, 09-09-2024
  • Power of attorney, Martine Aerts
  • Power of attorney, Oliver Leonhardt
  • Other provision, “Nom et qualité du notaire instrumentant ou de la personne ou des personnes ayant pouvoir de représenter la personne morale à l'égard des tiers, recto verso” (deed in French)
07-10
Gazette deed Permanent representatives: Piet Hemschoote and Filip Simpelaere
3 facts ▸
  • General meeting, 09-09-2024
  • Permanent representative, Piet Hemschoote
  • Permanent representative, Filip Simpelaere
10-07
NBB filing Annual accounts filed
financial year 2023 · full format
2023
27-11
Gazette deed Resignations & appointments
Power of attorney2 facts ▸
  • Board meeting, 05-10-2023
  • Power of attorney, Régine Tobback
04-10
Gazette deed Reappointment: Ernst & Young Réviseurs d'Entreprises SRL (statutory auditor)
2 facts ▸
  • General meeting, 30-06-2023
  • Auditor reappointment, Ernst & Young Réviseurs d'Entreprises SRL (statutory auditor)
Show earlier events
14-07
Gazette deed Resignations & appointments
Power of attorney · Director in office3 facts ▸
  • Board meeting, 21-06-2023
  • Power of attorney, Kris Vanderhoydonck (business unit manager adc belgium)
  • Director in office, Hendrikus A.M. Lueb (managing director)
05-07
NBB filing Annual accounts filed
financial year 2022 · full format
24-05
Gazette deed Resignations & appointments
Power of attorney3 facts ▸
  • Board meeting, 10-04-2023
  • Power of attorney, Maxime Labbé
  • Power of attorney, Freek Heuyerjans
2022
14-11
Gazette deed Resignation: Benjamin Edward Oosterbaan (director)
Appointment: Bradley Jay Slater (director)3 facts ▸
  • General meeting, 21-10-2022
  • Director resignation, Benjamin Edward Oosterbaan (director)
  • Director appointment, Bradley Jay Slater (director)
31-10
Gazette deed Capital & shares
Capital decrease · Amendment of the articles3 facts ▸
  • General meeting, 27-10-2022
  • Capital decrease, €246,108,367
  • Amendment of the articles, 5
23-08
NBB filing Annual accounts filed
financial year 2021 · full format · 23 days late
2021
27-07
NBB filing Annual accounts filed
financial year 2020 · full format
2020
23-09
NBB filing Annual accounts filed
financial year 2019 · full format · 54 days late
2019
30-12
NBB filing Annual accounts filed
financial year 2018 · full format · 152 days late
2018
27-09
NBB filing Annual accounts filed
financial year 2017 · full format · 58 days late
2017
29-06
NBB filing Annual accounts filed
financial year 2016 · full format
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.Of the 49 annual accounts filed, the latest 10 are here; all 49 are under Financials.
11 of 67 deeds read
About the unread acts

Of the 67 Belgian Official Gazette deeds we know for this company, 11 have been read. The other 56 have not been read yet: what they contain is neither established nor disproved here.

Have them read with priority Sign in to place this company at the front of the reading queue.

Register details

Identification
Legal formPublic limited company
Founded06-09-1948
Financial year end31-12
Activities, NACEBEL 2025
46460Wholesale of pharmaceutical and medical goods
E-invoicing
Reachable via Peppol
Peppol ID 0208:0403044007

If you follow this company, Checked tells you the day it leaves the Peppol register.

Register as of 29 October 2026 · Peppol Directory

Scores and ratios are computed by Checked and are not a credit decision.

Recognitions · licences · registrations

Legal Entity Identifier

5493000JGTEVCCT0C131
live in the LEI register

Environmental permits: No permit applications found in Flanders. Brussels and Wallonia do not publish the applicant.

Sites & property

Location & real-estate footprint
Registered office, Wavre · 1 establishment unit since 1977
registered office establishment The establishment unit on the map
Ground area
1.5 ha
Building footprint
832 m²
Building volume
15,549 m³
Parcel 25112N0041/00B000, Wallonia · tallest building 21.3 m. Linked by address, not a title deed.
3 companies at this address See who is registered here
1 establishment unit
ABBOTT
Avenue Einstein 14, 1300 WavreWholesale of pharmaceutical and medical goods
since 1977unit no. 2.005.628.715
1 parcel
Wallonia 1 (100%)
Cadastral parcel Region Area Buildings Height / floors
25112N0041/00B000 Wallonia 1.5 ha 1 · 832 m² 21.3 m · 6
How the parcels are linked
Good to know
The parcel matches the address exactly.